Background: Curcumin is a polyphenol, found in the spice turmeric, that has promising anticancer properties, but previous studies suggest that absorption of curcumin may be limited. Methods: This study examined the pharmacokinetics of a curcumin preparation in healthy human volunteers 0.25 to 72 h after a single oral dose. Curcumin was administered at doses of 10 g (n = 6) and 12 g (n = 6). Subjects were randomly allocated to dose level for a total of six subjects at each dose level. Serum samples were assayed for free curcumin, for its glucuronide, and for its sulfate conjugate. The data were fit to a onecompartment absorption and elimination model. Results: Using a high-performance liquid chromatography assay with a limit of detection of 50 ng/mL, only
Introduction
Wide arrays of phenolic substances, especially those present in dietary and medicinal plants, have been reported to possess substantial antioxidant, antiinflammatory, anticarcinogenic, and antimutagenic effects (1) (2) (3) . Curcumin is a yellow, naturally occurring polyphenolic phytochemical derived from turmeric, the powdered rhizome of the herb Curcuma longa Linn. The spice turmeric is used in curries as a coloring and flavoring agent in various parts of the world, especially in the Indian subcontinent, an area that has a low incidence of colorectal cancer (4) .
Several animal model studies have shown that curcumin suppresses carcinogenesis in skin (5-7), stomach (8, 9) , colon (10, 11) , breast (12) (13) (14) , and liver (15) . Curcumin is reported to induce apoptosis in a wide variety of tumor cells, including B-and T-cell leukemias (16, 17) , colon (18) , and breast carcinoma (19, 20) . Chemopreventive activities of curcumin are thought to involve up-regulation of carcinogen-detoxifying enzymes (21) (22) (23) and antioxidants (24, 25) , suppression of cyclooxygense-2 expression (26) (27) (28) (29) (30) , and inhibition of nuclear factor-nB release (30) (31) (32) . Inhibition of nuclear factor-nB release by curcumin also leads to the downregulation of various proinflammatory cytokines (e.g., tumor necrosis factor and interleukins) and inhibition of the mRNA expression of several proinflammatory enzymes (e.g., cyclooxygense, lipoxygenases, metalloproteinases, and nitric oxide synthase; ref. 33) .
In animal studies, curcumin undergoes rapid metabolic reduction and conjugation, resulting in poor systemic bioavailability after oral administration (34) (35) (36) . For example, an oral dose of 0.1 g/kg administered to mice yielded a peak plasma concentration of free curcumin that was only 2.25 Ag/mL (35) . In rats, curcumin completely disappeared from plasma within 1 h after a 40 mg/kg i.v. dose (34) . When given orally at a 500 mg/kg dose, peak concentrations of 1.8 ng/mL of free curcumin were detected in plasma (34) . The major metabolites of curcumin ( Fig. 1 ) identified in rat plasma were curcumin glucuronide and curcumin sulfate based on enzymatic hydrolysis studies. Hexahydrocurcumin, hexahydrocurcuminol, and hexahydrocurcumin glucuronide were also present in minor amounts (34) .
Data on the pharmacokinetic properties and metabolism of curcumin in humans are very limited. In a human study conducted in 25 patients with precancerous lesions, free curcumin concentrations (mean F SD) in plasma after taking 4, 6, and 8 g of curcumin per day for 3 months were 0.19, 0.20, and 0.60 Ag/mL, respectively (37) . None of the curcumin conjugates or metabolites of curcumin were reported in that study. A study of six patients with advanced colorectal cancer dosed with 3.6 g of curcumin daily for up to 3 months yielded 4.3, 5.8, and 3.3 ng/mL mean plasma concentrations of curcumin, curcumin glucuronide, and curcumin sulfate, respectively, 1 h after administration (38) .
In animal models, no toxicity has been reported to date. Similarly, in humans to date, few adverse events due to curcumin even at very high doses have been reported (7) . Whether the low toxicity is only a function of lack of bioavailability is an open question. We have recently reported a trial escalating curcuminoid dose from 0.5 to 10 g in healthy humans that showed few adverse events, but bioavailability of curcumin was limited (39) . The present clinical study assessed the complete pharmacokinetic profile of curcumin and its conjugate metabolites in healthy human subjects administered either a 10 g or a 12 g single dose, the highest doses given to humans. The aims of this study were to (a) determine if curcumin, in capsule formulation, is absorbed and biotransformed in humans and (b) assess the human pharmacokinetics of curcumin and its conjugate metabolites.
Materials and Methods
Curcuminoids were provided in a capsule form as a powder extract obtained from Alleppey finger turmeric (C 3 Complex, Sabinsa Corp.) in a standardized, Good Manufacturing Practice formulation. The mixture contained curcumin (75%), demethoxycurcumin (23%), and bisdemethoxycurcumin [2%; verified by highperformance liquid chromatography (HPLC) assay in our laboratory]. h-17-Estradiol acetate and the enzymes h-glucuronidase (type IX-A from Escherichia coli) and sulfatase (type H-1 from Helix pomatia) were purchased from Sigma-Aldrich, Inc. Sodium phosphate and sodium acetate (American Chemical Society certified) were purchased from Fisher Scientific. HPLC-grade ethyl acetate and methanol were purchased from Burdick and Jackson (Honeywell International, Inc.).
Clinical Trial Design. Twelve healthy human subjects solicited by advertisement or word of mouth, 18 y of age or older, with normal organ function were recruited. Subjects included five males and seven females (all Caucasian, ages 18-65 y, body mass index range of 20-29). Subjects were not taking any medications chronically. They were educated on food sources of curcumin and asked to avoid all foods containing high concentrations of curcumin within the 14 d before drug administration. Subjects completed a food checklist to verify that they were not consuming any curcumin-rich foods before dosing. A standardized, high-fat breakfast with 750 calories and 35 g of total fat (42% fat) designed to slow gastric emptying time was fed to all subjects to allow maximum absorption of curcumin, which is highly lipophilic. Then, curcumin was administered at a dose of 10 g (n = 6) or 12 g (n = 6). Subjects were randomly allocated to dose level for a total of six subjects at each dose level. Curcumin was formulated as Sabinsa C 
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Cancer Epidemiol Biomarkers Prev 2008;17 (6) . June 2008 incubation time was determined by a test run, where samples were incubated with enzymes for 1, 2, 3, 4, 5, 6, and 15 h, showing that the optimal incubation time was 3.5 h. The samples were extracted thrice with 1 mL of ethyl acetate/methanol (95:5, v/v) using the extraction procedure mentioned above. The extracts were then reconstituted in methanol (100 AL) before HPLC analysis. To determine the amount of glucuronide and sulfate conjugates in plasma, samples were incubated separately with h-glucuronidase and sulfatase enzymes before extraction.
Quantitation of Curcumin in Plasma. Reverse-phase HPLC was used to quantify curcumin in plasma. The separations were done on a ABondapak, C18 column (250 Â 4.6 mm inner diameter; 10 Am particle size; Waters) at room temperature. The mobile phase consisted of 0.1% acetic acid/65% methanol/35% water (v/v/v; A) and 100% methanol (B). The extracted sample was eluted on a gradient mobile phase starting 100% of A at zero time to 100% B in 15 min in a linear gradient and then to 100% A in 2 min at a flow rate of 2 mL/min. The injection volume for all samples was 20 AL and detection was done at 420 nm.
Standard curves were constructed using plasma added to curcumin. Plasma samples with no detectable curcumin (200 AL) were added to varying amount of a standard solution of curcumin to yield final curcumin concentrations of 0, 0.025, 0.05, 0.075, 0.10, 0.125, 0.25, 0.5, 1.25, 2.5, 5, and 10 Ag/mL, respectively. Spiked samples were extracted as described above. Calibration curves were obtained by plotting the area ratios of curcumin to internal standard, h-17-estradiol, against concentrations of curcumin in spiked plasma. Each sample was analyzed in duplicate.
Analytic Assessment/Quality Control. Curcumin and internal standards were well resolved by HPLC. Retention time of curcumin was 8.4 and internal standard was 11.0 min, respectively (Fig. 2) . A linear relationship between curcumin plasma concentration and peak area response was found in the concentration ranges 0.075 to 10 Ag/mL. Interday coefficients of determination (R 2 ) from 0.9979 to 0.9999 were observed over 4 d with curcumin-spiked plasma. The lower limit of quantitation of curcumin in plasma based on this method was 0.075 Ag/mL. The extraction efficiency of curcumin at 1.25 and 2.5 Ag/mL levels was 98.29% and 98.49%, respectively. The corresponding coefficients of variation were 1.8% and 1.2%, respectively. At 0.025 Ag/mL, the internal standard h-17-estradiol acetate showed 95.01% extraction efficiency with a coefficient of variation of 4%. The percentage recovery of curcumin at 1 Ag/mL was 95.14% with a coefficient of variation of 2.7%. The lower limit of detection was 0.050 Ag/mL.
We assayed the samples in random order, mixing samples from subjects receiving 10 and 12 g doses in assay batches (Fig. 3) . We matched the subject identification number on the plasma tube to the dose administered, raw HPLC chromatogram data sets, and to the pharmacokinetic study case report form to verify that samples were not misidentified in the assay procedure and correlate dose administered to each chromatogram after analysis was complete. Statistical Methods and Pharmacokinetic Analysis. Curcumin and curcumin conjugates were assessed in samples collected up to 72 h after dosing. The conjugate concentration of subject i at time t, c it , was modeled as a single-compartment pharmacokinetic process, with firstorder absorption and elimination:
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, and the SEs of those population means were calculated by means of the delta method. These primary model variables were estimated using SAS PROC NLINMIXED (SAS Institute), from which estimates of area under the curve (AUC), T max , C max , and t 1/2 were derived; their SEs and 95% confidence intervals, which describe the precision of the estimates, were calculated by means of the delta method (41) . Goodness of fit was evaluated by means of plots of observed versus predicted responses and plots of residuals versus time. Prediction intervals, which describe the distribution of values in the population, were estimated by parametric bootstrap (42) . It was observed from the raw data and model variables that the concentration profiles did not linearly increase with dose. The model above was rerun, with d i = 10 or d i = 10 + d, for subjects in the 10 and 12 g arms, respectively.
Results
Subjects and Adverse Events. Twelve healthy Caucasian subjects are shown in Table 1 (five males and No adverse events greater than grade 1 were reported. The major adverse events included one subject with headache and one with sore arms hours after dosing, likely unrelated to treatment, and two subjects with yellow, loose stool the day after dosing, most likely due to the lack of curcumin absorption in the gastrointestinal tract. One subject consumed curcumincontaining foods four times weekly but had no detectable curcumin or conjugates at baseline. Interestingly, this subject had the lowest AUC for curcumin glucuronide and curcumin sulfate compared with all other subjects.
Detection of Curcumin and Conjugate Metabolites in Plasma Samples
. Plasma samples of all subjects were analyzed with and without incubation with deconjugating enzymes using a slightly acidic pH because curcumin is not stable at pH 7.4. Figure 2 shows HPLC chromatograms of plasma with and without hydrolysis of conjugates. Free curcumin was detected in the plasma of only one subject without incubation, 30 min after ingestion of a 10 g dose. No free curcumin was detected in any other plasma samples from any other subject. Subsequent results refer exclusively to curcumin conjugates. C max , t 1/2 , and AUC of total curcumin conjugates calculated from the raw data are presented in Table 2 . One subject on the 10 g dose level had a T max of 10 h, but no curcumin conjugates were detected in this subject before 2 h and after 48 h of drug intake. When the T max was within the range of 1 to 4 h, curcumin conjugates were completely eliminated from plasma at the 24-h time point. The concentrations (mean F SD) of curcumin glucuronide and curcumin sulfate at T max at the 10 g dose level were 2.04 F 0.31 Ag/mL (range, 1.57-2.39 Ag/mL) and 1.06 F 0.40 Ag/mL (range, 0.44-1.62 Ag/mL), respectively, and at the 12 g dose level were 1.40 F 0.74 Ag/mL (range, 0.61-2.56 Ag/mL) and 0.87 F 0.44 Ag/mL (range, 0.41-1.65 Ag/mL), respectively ( Table 3) .
The kinetic variables of the total curcumin conjugates from the biexponential model are shown in Table 4 that the modeled C max and AUC are, like the direct estimates from the raw concentrations in Table 2 , greater for the 10 g than for the 12 g subjects. This difference was not due to a single outlier. Table 4 also presents estimates of the variation in AUC, C max , T max , and t 1/2 in the subjects. After a 10 g dose, 95% of the population would be expected to show C max between 0.71 and 7.04 Ag/mL, with half-life between 3.19 and 14.46 h.
The subjects in the 10 g dose group were similar in body mass index or mean age compared with the 12 g dose group (Table 1) . Pharmacokinetic variables were analyzed by sex, age, and body mass index but were not found to differ significantly based on these variables; however, this study was not powered to detect such differences.
The amount of glucuronide conjugate assessed at each participant's observed T max ranged between 20% and 67% higher than the concentration of sulfate conjugate (Table 3) . Total curcumin released after incubating plasma with h-glucuronidase and sulfatase enzymes separately was almost equal to the curcumin released after incubating plasma with h-glucuronidase and sulfatase enzymes together (Table 3) . These results indicate that most of the curcumin conjugates are either glucuronides or sulfates and not mixed conjugates.
Discussion
Prior clinical reports at lower doses have suggested that orally administered curcumin is poorly bioavailable. Gram doses were required to detect curcumin in blood, using 90% to 99% pure curcumin preparations, and the highest dose tested, 8 g, resulted in <1 Ag/mL curcumin (37, 38, 43) . A dose-escalation study detected free curcumin concentrations of 0.03 to 0.06 Ag/mL 1 to 4 h after a 10 or 12 g oral dose of curcuminoids in only one of three subjects at each dose level (39) . In the present single-dose pharmacokinetic study, we also failed to detect free curcumin in all but one subject using the Sabinsa curcuminoid (C 3 ) mixture that was 75% curcumin. Repetitive daily administration of curcumin may cause accumulation of curcumin at the gastrointestinal mucosal interface, resulting in more free curcumin delivered to systemic sites after multiple dosing, compared with a single dose (37, 38, 43) . Alternatively, at the extremely high doses we used, curcumin transport may be saturated at the gut epithelium, whereas conjugation is not. Curcumin absorption may not be limited. Rather, it may induce its own biotransformation (both conjugation and CYP reduction enzymes) in the gut epithelium or in the liver. In this scenario, one should detect proportionately higher conjugate concentrations at higher doses unless the excess conjugates are eliminated via the gut.
Data to date do not support the concept that curcumin serves as a prodrug (34, 44, 45) . For example, data suggest that tetrahydrocurcumin, a major reduction metabolite, is a less potent inhibitor of nuclear factornB, cyclooxygenase-1, 5-lipoxygenase, and proliferation at equivalent concentrations as curcumin (45, 46) . The potential biological effect of the high concentrations and long systemic exposure to conjugates remains unclear. Nevertheless, our findings that the majority of curcumin is biotransformed before measurement at the systemic (peripheral venous) site are consistent with the very low (38) . In this present study, a single high dose of curcumin resulted in rapid appearance of curcumin conjugates in human plasma with a lag of 0.68 h after dose with T max of f4 h as shown in Table 4 . In the rat, curcumin glucuronide and curcumin sulfate were the predominant metabolites (35, 36) . In a previously published human study, using 4 months of oral dosing of 3.6 g of curcumin daily, both glucuronide and sulfate conjugates were detected in plasma but at very low levels (3-6 ng/mL) similar to that of free curcumin (34) . Curcumin conjugates in our study were present at levels that were f1,000-fold higher (1-3 Ag/mL) when extracting curcumin after hydrolysis of conjugates. The present study suggests that curcumin was rapidly biotransformed at anatomic sites, potentially gastric mucosa, liver, or both, before peripheral venous circulation.
Surprisingly, the C max and AUC of curcumin conjugates in the 10 g arm were significantly higher than in the 12 g arm (P < 0.01; Table 4 ). Our review did not find bias in the sample handling, processing, or analytic procedures.
This outcome could be explained by saturation of a transport mechanism, resulting in no incremental curcumin absorption at higher doses, induction of metabolism at higher doses, and other mechanisms discussed earlier. Because the subjects took large numbers of capsules (40 capsules for the 10 g dose, 48 capsules for the 12 g dose), variation in the time required to swallow all of these capsules might have affected the absorption. The potentially longer time required to swallow the 48 capsule dose may have resulted in a lower C max and lower absorption compared with the 40 capsule dose.
In this trial, no serious adverse events were reported after curcumin dosing. All adverse events reported were grade 1. Although the small size of this trial precludes any formal safety end point analysis and statistical certainty of safety, the safety profile observed here is consistent with previous clinical and preclinical data (7, (37) (38) (39) .
A high rate of curcumin conjugation, through glucuronidation and sulfation, may explain low concentrations of free curcumin when administered orally in previous studies (34, 37, 38) . The potential activation of curcumin conjugates by intracellular glucuronidases or sulfatases should be explored further. Ireson et al. (34) reported that curcumin metabolites, specifically hexahydrocurcumin, tetrahydrocurcumin, and curcumin sulfate, had very low activity for inhibition of phorbol ester -induced prostaglandin E 2 production in human colonic epithelial cells compared with the parent compound. If, however, conjugates are deconjugated to free curcumin, as occurs in inflammation (47, 48) , one can speculate that the curcumin conjugate concentrations detected here are sufficient to modulate key curcumin-associated intracellular targets. In vitro, concentrations in the range of 3.6 to 36 Ag/mL of curcumin were necessary to modulate cellular targets (e.g., cyclooxygenase-2) in human colonic cells (30, 34) . The concentrations of curcumin conjugates observed in human plasma after consumption of 10 or 12 g single doses described here resulted in plasma concentrations sufficient to elicit pharmacologic activity in vitro, if deconjugated. Alternatively, curcumin conjugates have recently been shown to have interesting biological properties. Conjugation, therefore, may not necessarily be an inactivation pathway (49, 50) . Preliminary data in rodents have shown modulation of carcinogenesis targets at systemic sites after curcumin administration (10, 34, 51) .
The results of this study permit the following two conclusions to be drawn about oral curcumin in humans: (a) consumption of 10 or 12 g curcumin single doses generates mainly curcumin glucuronide and curcumin sulfate and (b) glucuronide conjugate predominates over sulfate conjugate in plasma with no evidence of a mixed conjugate being formed. These results indicate that curcumin is absorbed after oral administration and could be transported to sites other than the intestinal tract.
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